


Levamisole

Cat. No.:	HY-A0106		
CAS No.:	14769-73-4		
Molecular Formula:	C ₁₁ H ₁₂ N ₂ S		
Molecular Weight:	204.29		
Target:	nAChR; Parasite		
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (489.50 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	4.8950 mL	24.4750 mL	48.9500 mL
		5 mM	0.9790 mL	4.8950 mL	9.7900 mL
10 mM		0.4895 mL	2.4475 mL	4.8950 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (12.24 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Levamisole ((-)-Levamisole), an anthelmintic agent with immunomodulatory properties. Levamisole acts as a positive allosteric modulator (PAM) for the α3β2 (EC ₅₀ =300 μM) and α3β4 (EC ₅₀ =100 μM) subtype of nAChRs. Orally active ^{[1][2]} .
In Vivo	(S)-(-)-Levamisole (Levamisole) (50 μg/ml and 200 μg/ml; p.o.; 30 days) prevents weight gain in mice that were fed a high fat diet ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Environ Sci Pollut Res Int. 2022 Sep 16.
- Rapid Commun Mass Spectrom. 2022 Nov 16;e9430.
- bioRxiv. 2023 Oct 15.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lewis JA, et al. Levamisole: A Positive Allosteric Modulator for the $\alpha 3\beta 4$ Nicotinic Acetylcholine Receptors Prevents Weight Gain in the CD-1 Mice on a High Fat Diet. *Curr Pharm Des.* 2017;23(12):1869-1872.

[2]. Mehta KP, et al. Immunoregulatory treatment for minimal change nephrotic syndrome. *Arch Dis Child.* 1986;61(2):153-158.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA